Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$30.67 -4.74%

-$1.14 today

Market cap
$229.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.09M

Average 0.11M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$30.24M

FY 2025 · Annual

Investing Cash Flow

-$128,000.00

FY 2025 · Annual

Financing Cash Flow

$85.05M

FY 2025 · Annual

+425.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Depreciation & Amortization2.07M1.96M1.91M1.44M537K
Deferred Income Tax00000
Stock-Based Compensation2.32M4.52M4.37M4.11M3.84M
Change in Working Capital(221K)(8.42M)(3.93M)(836K)3.15M
Accounts Receivables0(1.98M)0(502K)2.33M
Inventory00000
Accounts Payables857K(2.04M)(133K)(228K)142K
Other Working Capital(1.08M)(4.4M)(3.8M)(106K)678K
Other Non-Cash Items1.67M(6.2M)325K41.22M204.26M
Operating Cash Flow(48.81M)(44.15M)(40.36M)(17.63M)(30.24M)
Capital Expenditures(1.27M)(728K)(398K)(26K)(128K)
Acquisitions (Net)0(39.04M)000
Purchases of Investments(91.74M)(29.6M)(28.04M)00
Sales of Investments15.3M68.64M80.17M00
Other Investing Activities039.04M000
Investing Cash Flow(77.71M)38.31M51.72M(26K)(128K)
Debt Repayment00000
Common Stock Issued124.22M42K280K16.04M85.05M
Common Stock Repurchased0(2.61M)(4K)00
Dividends Paid00000
Other Financing Activities410K(85K)280K133K0
Financing Cash Flow124.63M(2.57M)276K16.18M85.05M
Effect of Forex Changes00000
Net Change in Cash(1.89M)(8.4M)11.64M(1.48M)54.68M
Free Cash Flow(50.08M)(44.87M)(40.76M)(17.65M)(30.37M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$242.0M
+ D&A$537.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
+ Working Capital$3.2M
+ Other Non-Cash$204.3M
= Operating Cash Flow-$30.2M
- Capex-$128.0K
= Free Cash Flow-$30.4M

Analysis

FY2025 free cash flow is -$30.4M. FCF conversion is 12.5% of net income. Operating cash flow was -$30.2M, with capex of -$128.0K. The largest bridge item is Other Non-Cash at $204.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
FWPFWP filingNov 13, 2026
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13D/ASC 13D/A filingNov 6, 2026

Does SRZN generate free cash flow?

Surrozen, Inc. (SRZN) generated -$30.37M of free cash flow in fiscal 2025.

How much operating cash flow does SRZN produce?

Operating cash flow was -$30.24M, before capital expenditures of $128,000.00.